Vycor Medical (Vycor Medical) GF Score : 34/100 (As of May. 24, 2024)

View and export this data going back to 2009. Start your Free Trial

What is Vycor Medical GF Score?

Vycor Medical has the GF Score of 34, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 1/10
2. Profitability Rank : 2/10
3. Growth Rank : 1/10
4. GF Value Rank : 0/10
5. Momentum Rank : 7/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Vycor Medical might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Competitive Comparison of Vycor Medical's GF Score

For the Medical Devices subindustry, Vycor Medical's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vycor Medical's GF Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Vycor Medical's GF Score distribution charts can be found below:

* The bar in red indicates where Vycor Medical's GF Score falls into.

Vycor Medical (OTCPK:VYCO) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score	Performance Potential and All-in-One Screener Examples ⁽¹⁾
91 - 100	Highest outperformance potential
81 - 90	Good outperformance potential
71 - 80	Likely to have average performance
51 - 70	Poor future performance potential
0 - 50	Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Vycor Medical GF Score Related Terms

Thank you for viewing the detailed overview of Vycor Medical's GF Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Vycor Medical (Vycor Medical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Vycor Medical Inc (OTCPK:VYCO) » Definitions » GF Score

Comparable Companies

Traded in Other Exchanges

N/A

Address

951 Broken Sound Boulevard, Suite 320, Boca Raton, FL, USA, 33487

Website

https://www.vycormedical.com

Vycor Medical Inc is engaged in designing, developing and marketing medical devices for use in neurosurgery in the United States. It has developed ViewSite Brain Access System, which helps to reduce brain tissue trauma that arises from excessive pressure at the edges of the blade. It also provides non-invasive rehabilitation therapies for patients having disorders resulting from neurological brain damage caused by a stroke. The company operates through two segments: Vycor Medical, which focuses on devices for neurosurgery; and NovaVision, which focuses on neurostimulation therapies and diagnostic devices for the treatment and screening of visual field loss. The majority of the revenue comes from the Vycor Medical segment in the United States.

Executives

David Cantor	director, officer: President	1 PORTMAN HOUSE HUE STREET, ST HELIER, JERSEY CHANNEL ISLANDS X0 00000
Adrian Liddell	director, officer: Chairman	ROSEMOUNT, LYNCOMBE VALE ROAD, BATH HI BA2 4LP
Peter C Zachariou	director, 10 percent owner, officer: Chief Executive Officer	C/O QUE MANAGEMENT INC, 180 VENICK 13RH FL, NEW YORK NY 10014
Lowell Rush	director	C/O DIRECT INSITE CORP., 500 EAST BROWARD BOULEVARD, SUITE 1550, FORT LAUDERDALE FL 33394
Oscar Bronsther	director	4 AUTUMNWOOD COURT, THE WOODLANDS TX 77380
Steven Girgenti	director	C/O HEALTHWORLD CORP, 100 AVENUE OF THE AMERICAS, NEW YORK NY 10013
Fountainhead Capital Management Ltd	10 percent owner	PORTMAN HOUSE HUE STREET, ST HELIER, JERSEY CHANNEL ISLANDS X0 JE45RP

Vycor Medical (Vycor Medical) Headlines

From GuruFocus

New Study Shows Vision Rehab Treatment Effective for Stroke and Injury Related Blindness

By Marketwired Marketwired • 02-27-2020

Vycor Value Could be Unlocked with These Major Partnerships

By Last Financier Last Financier • 12-05-2014

Vycor Medical Reports Financial Results for the Year Ended December 31st, 2018

By ACCESSWIRE AccessWire • 04-12-2019

Vycor Medical, Inc. Agrees New NovaVision Licensing Agreement

By Marketwired Marketwired • 06-30-2020

Vycor Medical Reports Financial Results for the year ended December 31st, 2019

By Marketwired Marketwired • 03-27-2020

Vycor Medical Reports Financial Results for the Year Ended December 31st, 2017

By ACCESSWIRE AccessWire • 04-12-2019

Treatment for blindness successful in largest ever study

By Marketwired Marketwired • 02-26-2020